Healthtech Startups

ProviderTrust provides automated exclusion list monitoring to healthcare organizations to identify excluded individuals and entities from federal and state databases. The solution continuously screens employees, physicians, and vendors against multiple government exclusion lists to prevent fraud, waste, and abuse in healthcare operations.

2 investors

Proxima Bio is an early-stage biotechnology company developing protein degradation technology to target previously undruggable proteins for treatment of autoimmune conditions and cancers. The company is spun out of WEHI (Walter and Eliza Hall Institute) and based in Melbourne, Australia.

2 investors

Psilera is a biotech company developing neuroscience-focused therapeutics, including its lead asset PSIL-006, described as next-generation mindful medicine.

2 investors

Psygen is a licensed manufacturer of pharmaceutical-grade psychedelic active pharmaceutical ingredients for academic research, clinical trials, and authorized medical use. The company serves researchers, physicians, and healthcare systems working within regulated compassionate-use and special access programs.

2 investors

PTC is a global pharmaceutical company focused on the discovery, development, and commercialization of medicines for patients with rare diseases who have few or no treatment options. It combines clinical and scientific expertise to bring these treatments to patients worldwide.

2 investors

Puffpaw manufactures smart vapes with Bluetooth connectivity that track vaping activity and reward users with cryptocurrency tokens for reducing nicotine intake. The device uses an encrypted chip to store verifiable on-chain data and gamifies the experience of quitting nicotine addiction.

2 investors

Pulsatile Innovations develops Pulse Tile, a medical device focused on emergency cardiac care, particularly cardiac arrest. The company pursues TGA compliance and a Class IIb regulatory pathway for its healthcare technology in Australia.

2 investors

PulseTech is Bangladesh's leading tech-enabled pharmaceutical distributor rebuilding the supply chain that connects drug manufacturers to independent pharmacies. The company addresses fragmentation, inefficiency, and counterfeit medicines in the country's pharmacy retail market.

2 investors

PulseSight Therapeutics develops non-viral, plasmid-based gene therapies delivered via a proprietary electro-transfection system into the ciliary muscle to treat severe retinal diseases causing blindness. Its lead programs target late-stage dry AMD/geographic atrophy and wet AMD, with prior Phase 1/2 studies conducted in Europe and the USA.

2 investors

Pupilmed is a veterinary clinic offering internal medicine visits, vaccinations, deworming, specialist consultations, and emergency care for dogs and cats. It provides an online patient panel for tracking visit history and test results, free adaptation visits to reduce animal stress, and holistic care including behavioral and dietary support.

2 investors

Puray is a Munich-based medical technology startup developing medical tubing that uses far-UV photonic disinfection to kill pathogens, including antimicrobial-resistant germs, without harming human tissue. The product aims to prevent device-associated infections, reduce the frequency of tubing replacements, and conserve antibiotics in healthcare settings.

2 investors

Purespring develops genetic therapies targeting podocytes to treat renal diseases through its proprietary GlomThera platform. The company focuses on preserving kidney function in patients with large, underserved populations affected by renal disease.

2 investors

Pykus Therapeutics is a clinical-stage medical technology company developing biodegradable polymers for vitreoretinal surgery. Its lead product, PYK-2101, is a biodegradable hydrogel intended to help patients recover from retina surgery faster and more comfortably.

2 investors

Q-Sera is a biotech company backed by Australian investors Uniseed and Brandon BioCatalyst, emerging from University of Queensland commercialisation efforts.

2 investors

Q Therapeutics develops allogeneic, human glial progenitor cell therapies for currently incurable diseases of the central nervous system. Its lead candidate, Q-Cells, is an off-the-shelf cell therapy that replaces myelin and supports neuron repair, with FDA allowance to begin a Phase 1/2a trial in Transverse Myelitis patients.

2 investors

QbDVision provides a software platform designed to address digital transformation challenges in pharmaceutical and biotech manufacturing, helping companies manage compliance, quality, and process development.

2 investors

Qihan Biotech uses multiplexable genome editing and immune shielding technologies in human stem cells and animal germline cells to develop immune-privileged cell and organ therapies. It works on applications spanning organs such as kidney, heart, lung, and liver, as well as cell types including islet cells, cardiomyocytes, neurons, and immune cells.

2 investors

Qoniq provides data analysis and knowledge synthesis tools for Medical and Scientific Affairs professionals, helping them work with complex scientific datasets while augmenting rather than replacing human expertise.

2 investors

QRAGO is a transportation management platform that handles order processing, vehicle planning, routing, driver dispatch, and invoicing for medical facilities and logistics operations.

2 investors

Develops lateral flow assay (LFA) diagnostic test kits for urine-based and blood-based testing, offering a range of products across various test panels. The kits include the test kit, manual, and desiccant.

2 investors

Qu Biologics develops treatments aimed at cancer, chronic inflammatory diseases, and metabolic diseases by restoring normal immune function. It operates in the biotech and immunotherapy space.

2 investors

Quadlytics develops medical devices and software, provides healthcare services, and offers consulting on data analysis for the healthcare industry. The company is based in Japan with offices in Kyoto, Kobe, and Melbourne.

2 investors

Quadrant Eye develops at-home diagnostic technology to conduct comprehensive eye examinations. The platform aims to increase access to eye care services and help prevent avoidable vision loss.

2 investors

Quadria Capital is a healthcare-focused private equity firm with over $4 billion in assets under management, investing in healthcare businesses across South Asia and Southeast Asia to build regional leaders and drive social impact.

2 investors